BOULDER, Colo., Sept. 8 /PRNewswire/ — N30 Pharmaceuticals, LLC
today announced it has dosed the first human subject with N6022, a
first-in-class inhibitor of s-nitrosoglutathione reductase
(GSNOR).
N6022 is the first GSNOR inhibitor to be administered to human
beings. N6022 has the potential to be an important new treatment
for acute exacerbations of human diseases, such as asthma, chronic
obstructive pulmonary disease (COPD), inflammatory bowel disease
(IBD) and other inflammatory conditions.
About N6022 N6022 is the lead product in N30 Pharma’s
portfolio of drugs which are designed to treat asthma, COPD and
IBD. The initial Phase 1 testing in healthy subjects is designed to
evaluate the safety, tolerability and pharmacokinetics of single,
increasing intravenous dosages of N6022. Data from this
first-in-man trial will provide important safety, pharmacokinetic,
and biomarker information on which to base the design of subsequent
trials of N6022 as well as the development of reductase dosage
forms suitable for chronic administration.
Targeting GSNORGSNOR breaks down s-nitrosoglutahione (GSNO),
reducing the body’s pool of GSNO. In the lung, GSNO likely
plays an important role in maintaining normal respiratory function
through its influence on bronchial tone and anti-inflammatory
effects. Similarly, in the gut GSNO supports barrier
function and maintains the integrity of the gut surface. In
asthmatics, GSNOR upregulation and decreased GSNO levels have been
shown to contribute to respiratory disease, and genetic variants of
GSNOR have been correlated with disease susceptibility and poor
response to therapy. GSNO has also been found to be important
in the cardiovascular system as well as the control of
breathing.
About inhibitors of GSNORN30 Pharma’s portfolio of
proprietary compounds provides a platform of potent, selective and
reversible inhibitors of GSNOR. They increase levels of GSNO, a
s-nitrosothi
‘/>”/>
